ReviewNutrients2022
Mushroom Polysaccharides as Potential Candidates for Alleviating Neurodegenerative Diseases.
Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Ergothioneine-rich water extracts ofFrontiers in nutrition · 2026Article
- Artificial intelligence-assisted optimization of extraction enhances the biological activity of Phylloporia ribis.Scientific reports · 2025Article
- Extraction Optimization and Characterization of Antioxidant Polysaccharides FromFood science & nutrition · 2025Article
- Natural Neuroinflammatory Modulators: Therapeutic Potential of Fungi-Derived Compounds in Selected Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025Review
- Dietary Supplementation of Edible MushroomNutrients · 2025Article
- Supporting Neurologic Health with Mushroom Nutrition.Nutrients · 2025Review
- Unveiling the Therapeutic Potentials of Mushroom Bioactive Compounds in Alzheimer's Disease.Foods (Basel, Switzerland) · 2023Review
- Multiple Metabolites Derived from Mushrooms and Their Beneficial Effect on Alzheimer's Diseases.Nutrients · 2023Review
- An Immunomodulatory Polysaccharide-Protein Complex Isolated from the Polypore FungusJournal of fungi (Basel, Switzerland) · 2023Article
- First genome assembly and annotation ofFrontiers in cellular and infection microbiology · 2023Article
- New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs).Theranostics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Neurodegenerative diseases (NDs) are a widespread and serious global public health burden, particularly among the older population. At present, effective therapies do not exist, despite the increasing understanding of the different mechanisms of NDs. In recent years, some drugs, such as galantamine, entacapone, riluzole, and edaravone, have been proposed for the treatment of different NDs; however, they mainly concentrate on symptom management and confer undesirable side effects and adverse reactions. Therefore, there is an urgent need to find novel drugs with fewer disadvantages and higher efficacy for the treatment of NDs. Mushroom polysaccharides are macromolecular complexes with multi-targeting bioactivities, low toxicity, and high safety. Some have been demonstrated to exhibit neuroprotective effects via their antioxidant, anti-amyloidogenic, anti-neuroinflammatory, anticholinesterase, anti-apoptotic, and anti-neurotoxicity activities, which have potential in the treatment of NDs. This review focuses on the different processes involved in ND development and progression, highlighting the neuroprotective activities and potential role of mushroom polysaccharides and summarizing the limitations and future perspectives of mushroom polysaccharides in the prevention and treatment of NDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.